Low Income Subsidies (LIS in Part D) | Association for Accessible Medicines
Access! 2020 - Missed the early-bird? Save $300 off full-pass registration when you register by March 27

Low Income Subsidies (LIS in Part D)

AAM White Paper: Ensuring the Future of Accessible Medicines in the U.S.

Patient health and well-being depends on the uninterrupted availability of lower-cost generic and biosimilar medicines. Moreover, as patients live longer the importance of a robust and sustainable generic and biosimilar medicines industry becomes only that much more important. Policymakers must act quickly to ensure continued saving and market-based competition, as well as prevent shortages, for future availability of affordable medicines. This requires:

6 Policy Solutions

Association for Accessible Medicines is calling on Congress to take meaningful action to lower prescription drug costs with the Prescription for Savings. Patients win when market-based competition from FDA-approved generics and biosimilars deliver savings at the pharmacy counter.

To this end, we recommend these six policy solutions:

Subscribe to Low Income Subsidies (LIS in Part D)

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.